M&A Deal Summary |
|
|---|---|
| Date | 2024-03-14 |
| Target | Amolyt Pharma |
| Sector | Life Science |
| Buyer(s) | AstraZeneca |
| Sellers(s) |
Andera Partners
EQT Life Sciences |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.1B USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 45.8B USD (2023) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 18 of 19 |
| Sector (Life Science) | 16 of 17 |
| Type (Add-on Acquisition) | 14 of 15 |
| Country (France) | 1 of 1 |
| Year (2024) | 1 of 2 |
| Size (of disclosed) | 11 of 17 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-12-26 |
Gracell Biotechnologies
Suzhou, China Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. Gracell Biotechnologies was founded in 2017 and is based in Suzhou, China. |
Buy | $1.2B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-19 |
Fusion Pharmaceuticals
Hamilton, Ontario, Canada Fusion Pharmaceuticals is a pharmaceutical company focused on the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. Fusion Pharmaceuticals was formed in 2014 and is based in Hamilton, Ontario. |
Buy | $2.4B |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.7B EUR |
| Size | Large |
| Type | Sector Agnostic |
Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 38 of 40 |
| Sector (Life Science) | 7 of 7 |
| Type (Add-on Acquisition) | 13 of 14 |
| Country (France) | 28 of 29 |
| Year (2024) | 1 of 3 |
| Size (of disclosed) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-06 |
Groupe ADF
Vitrolles, France Groupe ADF is a provider of industrial engineering and maintenance services. Groupe ADF specialising in three business lines engineering & expertise, the supply of production and testing equipment, and production & maintenance services. Groupe ADF serves the Aeronautics, Space & Defense Industry, Energies, Oil & Gas sectors. Groupe ADF is based in Vitrolles, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-24 |
JenaValve Technology
Irvine, California, United States JenaValve Technology specializes in developing transcatheter aortic valves that can be implanted via the femoral vein or an incision between two ribs. JenaValve Technology was founded in 2006 and is based in Irvine, California. |
Sell | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1987 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Focused |
| DEAL STATS | # |
|---|---|
| Overall | 4 of 7 |
| Sector (Life Science) | 2 of 3 |
| Type (Add-on Acquisition) | 3 of 6 |
| Country (France) | 1 of 1 |
| Year (2024) | 1 of 4 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-09-06 |
Atlantic Therapeutics
Galway, Ireland Atlantic Therapeutics is a developer of professional and consumer medical devices, related software and connected health technologies. Atlantic Therapeutics with its product INNOVO focuses on the treatment of incontinence, sexual health dysfunctions and other associated disorders by strengthening the muscles and modulating the nerves of the pelvic floor. Atlantic Therapeutics was founded in 2017 and is based in Galway, Ireland. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-25 |
Cardior
Hannover, Germany Cardior is a clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair, and reverse diseases of the heart. The company's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. Cardior was founded in 2016 and is based in Hannover, Germany. |
Sell | $1.0B |
